Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIGHT-302: pemigatinib versus gemcitabine + cisplatin in first-line FGFR2-rearranged cholangiocarcinoma
jRCT2080224744Phase 3Completed
- Sponsor
- Incyte
- Start
- Jun 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of pemigatinib in cholangiocarcinoma (CCA) (2 arms), sponsored by Incyte. Primary endpoint: Progression-free survival. Started Jun 2019; status: completed.
02
Drugs
pemigatinib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on jRCT2080224744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224744.